Cravens & Co Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Cravens & Co Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,286	Closed	-$816K	–	58
2025 Q1	$816K	Buy	1,286 +123	+11%	+$84.6K	0.63%	34
2024 Q4	$828K	Sell	1,163 -142	-11%	-$119K	0.63%	33
2024 Q3	$1.37M	Buy	1,305 +71	+6%	+$79K	1.06%	16
2024 Q2	$1.3M	Sell	1,234 -57	-4%	-$55.3K	0.96%	16
2024 Q1	$1.24M	Buy	1,291 +7	+0.5%	+$6.66K	1.03%	19
2023 Q4	$1.13M	Sell	1,284 -16	-1%	-$13.2K	0.97%	19
2023 Q3	$1.07M	Buy	1,300 +71	+6%	+$55.8K	1.01%	17
2023 Q2	$883K	Sell	1,229 -10	-0.8%	-$7.71K	0.81%	26
2023 Q1	$1.02M	Sell	1,239 -8	-0.6%	-$6.03K	0.95%	17
2022 Q4	$900K	Buy	+1,247	New	+$920K	0.83%	21

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Cravens & Co Advisors's REGN Position: Q2 2025 in Review

Cravens & Co Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 1,286 shares — an estimated $816K sold.

Cravens & Co Advisors first reported a position in REGN in Q4 2022 and held it in 10 quarters. The position peaked at $1.37M in Q3 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Cravens & Co Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Cravens & Co Advisors sold 1,286 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $816K.
Cravens & Co Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 10 quarters.
Cravens & Co Advisors's Regeneron Pharmaceuticals position peaked at $1.37M in Q3 2024.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Cravens & Co Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.